Journal of Pediatric Hematology/Oncology · 2010 · 15 citations · 20 references
MedicineOncologyPharmacologyMolecular OncologyNeuro-oncologyPediatric OncologyBrain TumorsGlioblastomaMalignant NeoplasmsPediatric Brain TumorsPediatric Neuro-oncologySpinal TumorsGlioblastoma Targeted TherapyImmunohistochemical DetectionImmunohistochemical StainingMitogen-activated Protein Kinase CascadesMitogen-activated Protein Kinase ModulationRaf-mek-erk SignalingSorafenib TherapyValproic Acid
SUMMARY: Spinal glioblastoma multiforme (GBM) is rare in children. New therapeutic options should be explored given the poor outcomes reported. We describe the case of an infant with spinal GBM whose condition worsened despite radiotherapy and chemotherapy. Immunohistochemical analysis of the tumor sample showed activation of the Raf-MEK-ERK pathway. Targeted pharmacologic therapy with sorafenib plus valproic acid led to decrease in the size of the tumor and improvement of symptoms. We conclude that regulation of the mitogen-activated protein kinase pathway using sorafenib plus valproic acid warrants further investigation for the management of childhood GBM.
20
Descriptive epidemiology of primary spinal cord tumors
Kate A. Schellinger, Jennifer M. Propp, John L. Villano et al. · Journal of Neuro-Oncology · 2007 · 319 citations
Medicine, Neurosurgery, Oncology +14
Malignant astrocytomas of the spinal cord
Alan R. Cohen, Jeffrey H. Wisoff, Jeffrey C. Allen et al. · Journal of neurosurgery · 1989 · 282 citations
Medicine, Neurosurgery, Surgery +15
Intramedullary spinal cord tumors in children under the age of 3 years
Shlomo Constantini, John K. Houten, Douglas C. Miller et al. · Journal of neurosurgery · 1996 · 216 citations
Medicine, Neurosurgery, Surgery +15